The National Institute of Standards and Technology (NIST) is developing biomarker-based systems for cancer detection and treatment as part of the National Cancer Institute’s Early Detection Research Network. These systems employ advanced technologies like quantum dots and single-walled carbon nanotubes to improve cancer detection, diagnosis, prognosis, and treatment.
NIST is focusing on three main research lines:
1. Discovery of new cancer biomarkers, particularly mitochondrial DNA lesions that may indicate early cancer development
2. Validation of newly identified cancer biomarkers using quantum dot-based immunohistochemistry assays
3. Translation of established biomarkers like HER2 into clinical applications using novel materials and technologies
The ultimate goal is to develop clinically useful biomarker-based systems that can improve cancer detection, treatment, and patient outcomes.
Keywords: DNA/RNA, quantum dots, immunohistochemistry, nanocrystal, fluorophore
